Award & Investment Overview
Johns Hopkins Technology Ventures has selected nine faculty-led innovations for translational funding through three Johns Hopkins programs designed to move promising discoveries toward commercialization.
The awards provide non-dilutive funding for proof-of-concept studies, technology development, validation, and other activities required to reduce technical and commercial risk. The nine projects were selected from 89 applications through a newly consolidated application process covering the Cohen Translational Engineering Fund, Louis B. Thalheimer Fund for Translational Research, and Zizic Translational Fund.
Finalists presented their technologies to an external panel of investors, biotechnology leaders, and technology executives. Proposals were evaluated for innovation, scientific merit, prospective market impact, technical feasibility, and commercialization potential.
The individual award amounts and aggregate funding awarded were not disclosed.
Approach & Ecosystem Context
Johns Hopkins has developed a portfolio of philanthropic translational funds that can support technologies at different points between academic discovery and commercialization.
The Cohen Translational Engineering Fund provides early commercialization funding for Whiting School of Engineering faculty. The Thalheimer Fund supports proof-of-concept and validation work across Johns Hopkins technologies. The newly launched Zizic Translational Fund expands this translational support, particularly for biomedical innovations.
Bringing the three programs under a common application process is notable from a GAP program perspective. Researchers can enter through a single pathway while Johns Hopkins Technology Ventures directs promising opportunities toward the appropriate translational funding mechanism.
The 89 applications also demonstrate substantial internal demand for early commercialization capital. Selecting nine projects creates a focused portfolio in which funding can be directed toward experiments, prototypes, validation studies, and other milestones capable of determining whether technologies are ready for subsequent licensing, startup formation, industry partnerships, or follow-on financing.
Informed by the Mind the GAP initiative and GAP COA consortium activity, this portfolio illustrates the role philanthropic proof-of-concept and translational funds can play in creating continuity between research discovery and downstream commercialization.
Innovation & Technology
The Cohen Translational Engineering Fund selected two projects.
Susanna Thon is developing a self-powered photoelectrochemical system for carbon capture and release, building on research in nanomaterials, optoelectronics, solar energy conversion, and sensing.
Zongwei Zhou is advancing AI infrastructure for early cancer detection. The technology uses artificial intelligence to identify cancer at an early stage and is already being used in China, with the new funding supporting broader development.
The Thalheimer Fund selected four projects.
Mohammad Rezaee is advancing a biomolecular dosimeter for measuring and assessing radiation exposure.
Christine O’Hersey is developing Hypermelt, a microfluidic platform for detecting rare methylation biomarkers, with funding supporting further experimentation and validation.
Won Jin Ho is developing immunotherapeutic approaches targeting PTPN22 for immune-resistant cancers.
Mary Austin is developing UrInControl, an over-the-counter pessary intended to provide a more accessible treatment option for stress urinary incontinence.
The inaugural Zizic Translational Fund selected three biomedical projects.
Garry Cutting is developing targeted genetic editing approaches for inherited and acquired lung diseases.
Yun Guan is advancing MRGPRX1 allosteric modulators as a potential non-addictive approach to pain management.
Jonathan Schneck is developing targeted polymeric mRNA nanoparticles designed to generate CAR T cells directly in the body for potential autoimmune disease treatment.
Potential Market Uses and Applications
Self-Powered Photoelectrochemical Carbon Capture and Release
Potential Energy and Industrial Applications
- Carbon capture
- Industrial emissions management
- Carbon separation systems
- Sustainable industrial processes
AI Infrastructure for Early Cancer Detection
Potential Clinical Applications
- Early cancer detection
- AI-assisted diagnostics
- Medical imaging analysis
- Clinical decision support
Biomolecular Dosimeter for Radiation Dosimetry
Potential Clinical and Industrial Applications
- Radiation exposure assessment
- Radiation oncology
- Occupational radiation monitoring
- Emergency radiation response
Hypermelt
Potential Clinical Applications
- Rare biomarker detection
- Methylation analysis
- Molecular diagnostics
- Disease detection
PTPN22-Targeted Immunotherapy
Potential Clinical Applications
- Cancer immunotherapy
- Immune-resistant cancers
- Precision oncology
- Combination cancer therapies
UrInControl
Potential Clinical and Consumer Health Applications
- Stress urinary incontinence
- Women’s health
- Pelvic health
- Over-the-counter medical devices
Targeted Genetic Editing for Lung Diseases
Potential Clinical Applications
- Inherited lung diseases
- Acquired lung diseases
- Cystic fibrosis
- Genetic medicine
MRGPRX1 Allosteric Modulators
Potential Clinical Applications
- Non-addictive pain management
- Analgesics
- Acute pain
- Chronic pain
In Vivo CAR T Cell Generation
Potential Clinical Applications
- Autoimmune disease
- In vivo cell therapy
- CAR T therapy
- mRNA nanoparticle therapeutics
Related Topics
Johns Hopkins Technology Ventures, proof-of-concept funding, translational research, translational funding, university commercialization, Cohen Translational Engineering Fund, Thalheimer Fund, Zizic Translational Fund, medical devices, therapeutics, artificial intelligence, carbon capture
About innovosource
innovosource tracks GAP programs, including proof-of-concept programs, startup accelerators, translational research initiatives, university venture funds, and commercialization ecosystems that help move university innovations from research to market.
Our coverage is informed by the Mind the GAP initiative and the GAP COA consortium activity, providing practical insights into the evolving commercialization landscape.
Learn more:
